Enhancing bispecific antibody therapies with healthy donor T cells (Innolink: 100.763 IP-LS)

• Unité de recherche: INNOSUISSE
• Numéro de projet: 61834.1 IP-LS
• Titre du projet anglais: Enhancing bispecific antibody therapies with healthy donor T cells (Innolink: 100.763 IP-LS)

Description succincte (Allemand)

Enhancing bispecific antibody therapies with healthy donor T cells (Innolink: 100.763 IP-LS)

Description succincte (Anglais)

Enhancing bispecific antibody therapies with healthy donor T cells

Résumé des résultats (Abstract) (Allemand)

Bispecific antibodies (biAbs) rely on autologous T cells which, in cancer patients, are often insufficient. Encelta has developed Allogeneic-Engineered-Decoupled (AED) T cells from healthy donors that can be used safely (no GvHD) and effectively against tumor cells when activated with a biAb.